Competing treatments for migraine: a headache for decision-makers

BACKGROUND: Migraine is the world’s second most common disabling disorder, affecting 15% of UK adults and costing the UK over £1.5 billion per year. Several costly new drugs have been approved by National Institute for Health and Care Excellence. AIM: To assess the cost-effectiveness of drugs used t...

Descripción completa

Detalles Bibliográficos
Autores principales: Mistry, Hema, Naghdi, Seyran, Underwood, Martin, Duncan, Callum, Madan, Jason, Matharu, Manjit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10696771/
http://dx.doi.org/10.1186/s10194-023-01686-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10696771/
http://dx.doi.org/10.1186/s10194-023-01686-y

Ejemplares similares